RTI Surgical Announces Commercial Launch of Fortilink-TS and -L IBF Systems with TETRAfuse 3D Technology

Medical Device Investing

RTI Surgical (Nasdaq:RTIX), a global surgical implant company, announced the full commercial launch of its Fortilink-TS and -L IBF Systems, adding to a growing series of interbody fusion devices featuring proprietary TETRAfuse® 3D Technology. The Fortilink-TS and -L Systems are intended for use in lumbar interbody fusion procedures at one or two adjoining levels in …

RTI Surgical (Nasdaq:RTIX), a global surgical implant company, announced the full commercial launch of its Fortilink-TS and -L IBF Systems, adding to a growing series of interbody fusion devices featuring proprietary TETRAfuse® 3D Technology. The Fortilink-TS and -L Systems are intended for use in lumbar interbody fusion procedures at one or two adjoining levels in patients with degenerative disc disease. TETRAfuse 3D Technology is the first 3D printed polymer-based interbody fusion device to incorporate a nano-roughi surface that has demonstrated, in a pre-clinical study, more notable trabecular bone ingrowth compared to PEEK and titanium-coated PEEKii.

As quoted in the press release:

“The Fortilink-L System is the first osteointegrative, radiolucent cage,” said Joseph O’Brien, M.D., M.P.H., founder of the Washington Spine & Scoliosis Institute at OrthoBethesda in Bethesda, Maryland, and one of the first surgeons to implant the Fortilink-L device. “While other companies are focusing on titanium, TETRAfuse 3D Technology offers ingrowth features that help the implant to fully integrate with the fusing bone. It also has best-in-class X-ray compatibility, which allows me to track my patients’ progress with more confidence.”

John O’Toole, M.D., M.S., Professor of Neurosurgery at Rush University Medical Center in Chicago, Illinois, and one of the first surgeons to implant the Fortilink-TS device, added, “The introduction of TETRAfuse 3D Technology revolutionizes the interbody device market by combining a favorable modulus of elasticity, optimal imaging characteristics and a surface design promoting vigorous bone ingrowth. I believe TETRAfuse 3D Technology meets all the criteria for an interbody through enhanced biology, biomechanics and ease of use to help improve outcomes for patients.”

Click here to read the full press release.

The Conversation (0)
×